Cargando…
Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement
Autores principales: | Fleming, Andrew B., Raabe, Vanessa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187833/ https://www.ncbi.nlm.nih.gov/pubmed/32361326 http://dx.doi.org/10.1016/j.jcv.2020.104388 |
Ejemplares similares
-
Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!
por: Sanfilippo, F., et al.
Publicado: (2020) -
Current Perspectives of convalescent plasma therapy in COVID-19
por: Sahu, Kamal Kant, et al.
Publicado: (2020) -
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
por: Joyner, Michael J., et al.
Publicado: (2021) -
Functional Antibodies in COVID-19 Convalescent Plasma
por: Herman, Jonathan D., et al.
Publicado: (2021) -
Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
por: Raadsen, Matthijs P., et al.
Publicado: (2021)